[go: up one dir, main page]

Ding et al., 2021 - Google Patents

Advances in genome editing for genetic hearing loss

Ding et al., 2021

View PDF
Document ID
13692180711867365774
Author
Ding N
Lee S
Lieber-Kotz M
Yang J
Gao X
Publication year
Publication venue
Advanced drug delivery reviews

External Links

Snippet

Abstract According to the World Health Organization, hearing loss affects over 466 million people worldwide and is the most common human sensory impairment. It is estimated that genetic factors contribute to the causation of approximately 50% of congenital hearing loss …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Similar Documents

Publication Publication Date Title
Ding et al. Advances in genome editing for genetic hearing loss
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
Ratican et al. Progress in gene therapy to prevent retinal ganglion cell loss in glaucoma and Leber’s hereditary optic neuropathy
WO2016111546A3 (en) Endonuclease targeting blood coagulation factor viii gene and composition for treating hemophilia comprising same
Torrecilla et al. Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis
WO2016201380A8 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2004027033A3 (en) Lentiviral vector-mediated gene transfer and uses thereof
DE60237158D1 (en) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2002088320A3 (en) Raav-vectored ribozyme compositions and methods for the treatment of retinal diseases
WO2020257610A8 (en) Optimized bacteria engineered to treat disorders involving the catabolism of leucine, isoleucine, and/or valine
WO2008049058A3 (en) Cln2 treatment of alzheimer's disease
ATE423574T1 (en) DOMINANT-NEGATIVE PLB MUTANT FOR THE TREATMENT OF HEART DISEASES
DE50009365D1 (en) MEANS OF TREATMENT OF MALIGNER DISEASES USING THE PROTEIN YB-1
DE69833876D1 (en) COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF BIOLOGICAL ACTIVE FACTORS
Fu et al. Gene therapy for hereditary hearing loss
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2002077161A3 (en) Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
Beyrau et al. Outcomes of primary scleral buckling for stage 4 retinopathy of prematurity
ITMI20030860A1 (en) METHOD FOR SELECTIVE INHIBITION OF THE N-MYC GENE
AU5155700A (en) Gene therapy of pulmonary disease
EP1143996A4 (en) METHOD FOR TREATING CHRONIC HEART DISEASES
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma